Abstract

Studying and analyzing of complex molecular mechanisms and immunological processes of cancer enables oncology to introduce new cancer therapies. In the treatment of cancer, we successively increase the use of targeted therapies with tyrosine kinase inhibitors and mTOR inhibitors and immunotherapy using checkpoint inhibitors CTLA-4 (cytotoxic T-cell antigen-4) and PD-1/PD-L1 (programmed death receptor 1/programmed death ligand 1). New anticancer drugs gradually replace conventional chemotherapy and have already found application in the treatment of many cancers, including thyroid cancer, hepatocellular carcinoma, non-small cell lung cancer, kidney cancer, bladder cancer, melanoma, breast cancer, acute and chronic myelogenous leukemia. The use of these drugs is less toxic than classical chemotherapy, but it can cause gastrointestinal, cardiovascular, respiratory, skin and endocrine complications. Most of the side effects of new cancer therapies are mild and moderate disorders, however some might be severe and life-threatening. Endocrinopathies are one of the more common side effects of these treatments. They can affect many endocrine glands (pituitary, thyroid, parathyroid, adrenal, pancreas) and cause both transient and permanent disorders.

References

• 1. Abdulrahman R.M., Verloop H., Hoftijzer H., Verburg E., HovensG.C., Corssmit E.P., Reiners C., Gelderblom H., Pereira A.M.,Kapiteijn E., Romijn J.A., Visser T.J., Smit J.W.: Sorafenib-inducedhypothyroidism is associated with increased type 3 deiodination.J. Clin. Endocrinol. Metab., 2010; 95: 3758–3762
  Google Scholar
• 2. Angell T.E.: Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associatedwith improved overall survival. Clin. Thyroidol., 2020; 32: 65–68
  Google Scholar
• 3. Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M.,Kageyama K., Imagawa A., Akamizu T.: Management of immunerelatedadverse events in endocrine organs induced by immunecheckpoint inhibitors: clinical guidelines of the Japan EndocrineSociety. Endocr. J., 2019; 66: 581–586
  Google Scholar
• 4. Baldazzi V., Tassi R., Lapini A., Lunghi A., Garofoli E., Caruso S.,Carini M., Mazzanti R.: Sunitinib-induced hyperparathyroidism:A possible mechanism to altered bone homeostasis. Cancer, 2012;118: 3165–3172
  Google Scholar
• 5. Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S.,Min L., Krop I.E., Tolaney S.M.: Incidence of endocrine dysfunctionfollowing the use of different immune checkpoint inhibitorregimens: A systematic review and meta-analysis. JAMA Oncol.,2018; 4: 173–182
  Google Scholar
• 6. Bjornsti M.A., Houghton P.J: The TOR pathway: A target forcancer therapy. Nat. Rev. Cancer, 2004; 4: 335–348
  Google Scholar
• 7. Blagosklonny M.V.: Fasting and rapamycin: Diabetes versus benevolentglucose intolerance. Cell Death Dis., 2019; 10: 607
  Google Scholar
• 8. Blagosklonny M.V.: Rapamycin for longevity: Opinion article.Aging, 2019; 11: 8048–8067
  Google Scholar
• 9. Brancatella A., Viola N., Brogioni S., Montanelli L., Sardella C.,Vitti P., Marcocci C., Lupi I., Latrofa F.: Graves’ disease induced byimmune checkpoint inhibitors: A case report and review of theliterature. Eur. Thyroid J., 2019; 8: 192–195
  Google Scholar
• 10. Braun D., Kim T.D., le Coutre P., Köhrle J., Hershman J.M., SchweizerU.: Tyrosine kinase inhibitors noncompetitively inhibitMCT8-mediated iodothyronine transport. J. Clin. Endocrinol. Metab.,2012; 97: E100–E105
  Google Scholar
• 11. Buffier P., Bouillet B., Smati S., Archambeaud F., Cariou B.,Verges B.: Expert opinion on the metabolic complications of newanticancer therapies: Tyrosine kinase inhibitors. Ann. Endocrinol.,2018; 79: 574–582
  Google Scholar
• 12. Castinetti F., Albarel F., Archambeaud F., Bertherat J., BouilletB., Buffier P., Briet C., Cariou B., Caron P., Chabre O., ChansonP., Cortet C., Do Cao C., Drui D., Haissaguerre M. i wsp.: Endocrineside-effects of new anticancer therapies: Overall monitoring andconclusions. Ann. Endocrinol., 2018; 79: 591–595
  Google Scholar
• 13. Castinetti F., Borson-Chazot F.: Introduction to expert opinionon endocrine complications of new anticancer therapies. Ann. Endocrinol.,2018; 79: 535–538
  Google Scholar
• 14. Clemons J., Gao D., Naam M., Breaker K., Garfield D., Flaig T.W.:Thyroid dysfunction in patients treated with sunitinib or sorafenib.Clin. Genitourin. Cancer, 2012; 10: 225–231
  Google Scholar
• 15. Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., SalvatoriR., Torino F.: Endocrine side effects induced by immune checkpointinhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375
  Google Scholar
• 16. Darvin P., Toor S.M., Nair V.S, Elkord E.: Immune checkpointinhibitors: Recent progress and potential biomarkers. Exp. Mol.Med., 2018; 50: 1–11
  Google Scholar
• 17. de Filette J., Andreescu C.E., Cools F., Bravenboer B., VelkeniersB.: A systematic review and meta-analysis of endocrine-relatedadverse events associated with immune checkpoint inhibitors.Horm. Metab. Res., 2019; 51: 145–156
  Google Scholar
• 18. de Filette J.M., Pen J.J., Decoster L., Vissers T., Bravenboer B.,Van der Auwera B.J., Gorus F.K., Roep B.O., Aspeslagh S., Neyns B.,Velkeniers B., Kharagjitsingh A.V.: Immune checkpoint inhibitorsand type 1 diabetes mellitus: A case report and systematic review.Eur. J. Endocrinol., 2019; 181: 363–374
  Google Scholar
• 19. Deligiorgi M.V., Panayiotidis M.I., Trafalis D.T.: Parathyroidhormone related protein (PTHrP)-mediated hypercalcemia in malignancyassociated with anti-PD-1 immune checkpoint inhibitortreatment and related inflammatory reactions. Int. Immunopharmacol.,2019; 77: 105942
  Google Scholar
• 20. Demetri G.D., von Mehren M., Blanke C.D., Van den AbbeeleA.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., SingerS., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., CapdevilleR., Kiese B. i wsp.: Efficacy and safety of imatinib mesylate inadvanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002;347: 472–480
  Google Scholar
• 21. Feldt S., Schüssel K., Quinzler R., Franzmann A., Czeche S.,Ludwig W.D., Schulz M.: Incidence of thyroid hormone therapy inpatients treated with sunitinib or sorafenib: A cohort study. Eur.J. Cancer, 2012; 48: 974–981
  Google Scholar
• 22. Fountas A., Diamantopoulos L.N., Tsatsoulis A.: Tyrosine kinaseinhibitors and diabetes: A novel treatment paradigm? TrendsEndocrinol. Metab., 2015; 26: 643–656
  Google Scholar
• 23. Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M.,Castel J., Berthault M.F., Magnan C., Cerasi E., Kaiser N., LeibowitzG.: mTOR inhibition by rapamycin prevents – β cell adaptation tohyperglycemia and exacerbates the metabolic state in type 2 diabetes.Diabetes, 2008; 57: 945–957
  Google Scholar
• 24. Green M.R., Newton M.D., Fancher K.M.: Off-target effects ofBCR-ABL and JAK2 inhibitors. Am. J. Clin. Oncol., 2016; 39: 76–84
  Google Scholar
• 25. Guertin D.A, Sabatini D.M.: Defining the role of mTOR in cancer.Cancer Cell, 2007; 12: 9–22
  Google Scholar
• 26. Gutierrez C., McEvoy C., Munshi L., Stephens R.S., Detsky M.E.,Nates J.L., Pastores S.M.: Critical care management of toxicities associatedwith targeted agents and immunotherapies for cancer.Crit. Care Med., 2020; 48: 10–21
  Google Scholar
• 27. Hay N., Sonenberg N.: Upstream and downstream of mTOR.Genes Dev., 2004; 18: 1926–1945
  Google Scholar
• 28. Iyer P.C, Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S.,Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immunerelatedthyroiditis with immune checkpoint inhibitors. Thyroid,2018; 28: 1243–1251
  Google Scholar
• 29. Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., de KrijgerR.R., Eechoute K., Mathijssen R.H.J., Sleijfer S., Leijten F., DanserA.H.J., van den Meiracker A.H., Visser T.J.: Sunitinib-induced hypothyroidismis due to induction of type 3 deiodinase activity andthyroidal capillary regression. J. Clin. Endocrinol. Metab., 2011;96: 3087–3094
  Google Scholar
• 30. Kassi E., Angelousi A., Asonitis N., Diamantopoulos P., AnastasopoulouA., Papaxoinis G., Kokkinos M., Giovanopoulos I.,Kyriakakis G., Petychaki F., Savelli A., Benopoulou O., Gogas H.:Endocrine-related adverse events associated with immune‐checkpointinhibitors in patients with melanoma. Cancer Med., 2019;8: 6585–6594
  Google Scholar
• 31. Kitajima K., Takahashi S., Maeda T., Yoshikawa T., Ohno Y., FujiiM., Miyake H., Fujisawa M., Sugimura K.: Thyroid size change byCT monitoring after sorafenib or sunitinib treatment in patientswith renal cell carcinoma: Comparison with thyroid function. Eur.J. Radiol., 2012; 81: 2060–2065
  Google Scholar
• 32. Kluczyński Ł., Gilis-Januszewska A., Rogoziński D., PantoflińskiJ., Hubalewska-Dydejczyk A.: Hypophysitis-new insights into diagnosisand treatment. Endokrynol. Pol., 2019; 70: 260–269
  Google Scholar
• 33. Kobayashi T., Iwama S., Yasuda Y., Okada N., Tsunekawa T.,Onoue T., Takagi H., Hagiwara D., Ito Y., Morishita Y., Goto M., Suga H., Banno R., Yokota K. i wsp.: Patients with antithyroid antibodiesare prone to develop destructive thyroiditis by nivolumab:A prospective study. J. Endocr. Soc., 2018; 2: 241–251
  Google Scholar
• 34. Kotwal A., Haddox C., Block M., Kudva Y.C.: Immune checkpointinhibitors: An emerging cause of insulin-dependent diabetes. BMJOpen Diab. Res. Care, 2019; 7: e000591
  Google Scholar
• 35. Kraig E., Linehan L.A., Liang H., Romo T.Q., Liu Q., Wu Y., BenavidesA.D., Curiel T.J., Javors M.A., Musi N., Chiodo L., Koek W.,Gelfond J.A.L., Kellogg D.L.Jr.: A randomized control trial to establishthe feasibility and safety of rapamycin treatment in an olderhuman cohort: Immunological, physical performance, and cognitiveeffects. Exp. Gerontol., 2018; 105: 53–69
  Google Scholar
• 36. Krajewska J., Paliczka-Cieslik E., Jarzab B.: Managing tyrosinekinase inhibitors side effects in thyroid cancer. Expert Rev. Endocrinol.Metab., 2017; 12: 117–127
  Google Scholar
• 37. Król A., Gawlik T., Jarząb B.: Endocrine complications of cancerimmunotherapy. Endokrynol. Pol., 2018; 69: 722–733
  Google Scholar
• 38. Kroschinsky F., Stölzel F., von Bonin S., Beutel G., KochanekM., Kiehl M., Schellongowski P., Intensive Care in Hematologicaland Oncological Patients (iCHOP) Collaborative Group: New drugs,new toxicities: Severe side effects of modern targeted and immunotherapyof cancer and their management. Crit. Care, 2017; 21: 89
  Google Scholar
• 39. Kyi C., Postow M.A.: Checkpoint blocking antibodies in cancerimmunotherapy. FEBS Lett., 2014; 588: 368–376
  Google Scholar
• 40. Lanzolla G., Coppelli A., Cosottini M., Del Prato S., Marcocci C.,Lupi I.: Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmunepolyendocrine syndrome. J. Endocr. Soc., 2019; 3: 496–503
  Google Scholar
• 41. Li J., Wang M., Zhang B., Wu X., Lin T.L., Liu X.F., Zhou Y., ZhangX.H., Xu H., Shen L.J., Zou J., Lu P., Zhang D., Gu W.J., Zhang M.X.,Pan J., Cao H., Chinese Society of Surgeons for GastrointestinalStromal Tumor of the Chinese Medical Doctor Association: Chineseconsensus on management of tyrosine kinase inhibitor-associatedside effects in gastrointestinal stromal tumors. World J. Gastroenterol.,2018; 24: 5189–5202
  Google Scholar
• 42. Liu S., Kurzrock R.: Toxicity of targeted therapy: Implicationsfor response and impact of genetic polymorphisms. Cancer Treat.Rev., 2014; 40: 883–891
  Google Scholar
• 43. Lu J., Li L., Lan Y., Liang Y., Meng H.: Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic reviewand meta-analysis. Cancer Med., 2019; 8: 7503–7515
  Google Scholar
• 44. Lupu J., Pages C., Laly P., Delyon J., Laloi M., Petit A., Basset-Seguin N., Oueslati I., Zagdanski A.M., Young J., Bouche C., LebbéC., Gautier J.F.: Transient pituitary ACTH-dependent Cushing syndromecaused by an immune checkpoint inhibitor combination.Melanoma Res., 2017; 27: 649–652
  Google Scholar
• 45. Makita N., Iiri T.: Tyrosine kinase inhibitor-induced thyroiddisorders: A review and hypothesis. Thyroid, 2013; 23: 151–159
  Google Scholar
• 46. Makita N., Miyakawa M., Fujita T., Iiri T.: Sunitinib induceshypothyroidism with a markedly reduced vascularity. Thyroid,2010; 20: 323–326
  Google Scholar
• 47. Mannavola D., Coco P., Vannucchi G., Bertuelli R., Carletto M.,Casali P.G., Beck-Peccoz P., Fugazzola L.: A novel tyrosine-kinaseselective inhibitor, sunitinib, induces transient hypothyroidismby blocking iodine uptake. J. Clin. Endocrinol. Metab., 2007; 92:3531–3534
  Google Scholar
• 48. Marcq E., Waele J.D., Audenaerde J.V., Lion E., SantermansE., Hens N., Pauwels P., van Meerbeeck J.P., Smits E.L.J.: Abundantexpression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapycheckpoint targets in effusions of mesothelioma patients. Oncotarget,2017; 8: 89722–89735
  Google Scholar
• 49. Martins F., de Oliveira M.A., Wang Q., Sonis S., Gallottini M.,George S., Treister N.: A review of oral toxicity associated withmTOR inhibitor therapy in cancer patients. Oral Oncol., 2013; 49:293–298
  Google Scholar
• 50. Matrana M.R., Duran C., Shetty A., Xiao L., Atkinson B.J., CornP., Pagliaro L.C., Millikan R.E., Charnsangave C., Jonasch E., TannirN.M.: Outcomes of patients with metastatic clear-cell renal cell carcinomatreated with pazopanib after disease progression with othertargeted therapies. Eur. J. Cancer, 2013; 49: 3169–3175
  Google Scholar
• 51. Min L., Vaidya A., Becker C.: Thyroid autoimmunity and ophthalmopathyrelated to melanoma biological therapy. Eur. J. Endocrinol.,2011; 164: 303–307
  Google Scholar
• 52. Neumann D., Korzeniowska K., Jankowski J., Jabłecka A.:Kardiotoksyczność leczenia przeciwnowotworowego. Chor. SercaNaczyń, 2016; 13: 434–444
  Google Scholar
• 53. Nurgali K., Jagoe R.T., Abalo R.: Adverse effects of cancer chemotherapy:Anything new to improve tolerance and reduce sequelae?Front Pharmacol., 2018; 9: 245
  Google Scholar
• 54. Ohba K., Takayama T., Matsunaga H., Matsushita A., Sasaki S.,Oki Y., Ozono S., Nakamura H.: Inappropriate elevation of serumthyrotropin levels in patients treated with axitinib. Thyroid, 2013;23: 443–448
  Google Scholar
• 55. Pal S.K., Miller M.J., Agarwal N., Chang S.M., Chavez-MacGregorM., Cohen E., Cole S., Dale W., Magid Diefenbach C.S., Disis M.L.,Dreicer R., Graham D.L., Henry N.L., Jones J., Keedy V. i wsp.: Clinicalcancer advances 2019: Annual report on progress against cancerfrom the American Society of Clinical Oncology. J. Clin. Oncol.,2019; 37: 834–849
  Google Scholar
• 56. Paul M.K., Mukhopadhyay A.K.: Tyrosine kinase – Role and significancein cancer. Int. J. Med. Sci., 2004; 1: 101–115
  Google Scholar
• 57. Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immunecheckpoint inhibitor-induced hypoparathyroidism associated withcalcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol.Metab., 2019; 104: 550–556
  Google Scholar
• 58. Płużański A., Piórek A.: Side effects of tyrosine kinase inhibitors— management guidelines. Oncol. Clin. Pract., 2016; 12: 113–118
  Google Scholar
• 59. Prete A., Salvatori R.: Hypophysitis. https://www.ncbi.nlm.nih.gov/books/NBK519842 (15.08.2018)
  Google Scholar
• 60. Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L.,Reddy S., Dreicer R., Bukowski R.M.: Hypothyroidism in patientswith metastatic renal cell carcinoma treated with sunitinib. J. Nat.Cancer Inst., 2007; 99: 81–83
  Google Scholar
• 61. Sagiv O., Kandl T.J, Thakar S.D., Thuro B.A, Busaidy N.L., CabanillasM., Jimenez C., Dadu R., Graham P.H., Debnam J.M., Esmaeli B.:Extraocular muscle enlargement and thyroid eye disease-like orbitalinflammation associated with immune checkpoint inhibitor therapyin cancer patients. Ophthalmic Plast. Reconstr. Surg., 2019; 35: 50–52
  Google Scholar
• 62. Santoni M., Conti A., Massari F., Di Nunno V., Faloppi L., GaliziaE., Morbiducci J., Piva F., Buti S., Iacovelli R., Ferretti B., CimadamoreA., Scarpelli M., Lopez-Beltran A., Cheng L., Battelli N., MontironiR.: Targeted therapy for solid tumors and risk of hypertension: Ameta-analysis of 68077 patients from 93 phase III studies. Exp. Rev.Cardiovasc. Ther., 2019; 17: 917–927
  Google Scholar
• 63. Shu M., Zai X., Zhang B., Wang R., Lin Z.: Hypothyroidism sideeffect in patients treated with sunitinib or sorafenib: Clinical andstructural analyses. PLoS One, 2016; 11: e0147048
  Google Scholar
• 64. Sivendran S., Agarwal N., Gartrell B., Ying J., Boucher K.M.,Choueiri T.K., Sonpavde G., Oh W.K., Galsky M.D.: Metabolic complicationswith the use of mTOR inhibitors for cancer therapy. CancerTreat. Rev., 2014; 40: 190–196
  Google Scholar
• 65. Sobańska K., Szałek E., Kamińska A., Grześkowiak E.: Inhibitorykinaz tyrozynowych w terapii przeciwnowotworowej. Farm.Współ., 2011; 4: 185–190
  Google Scholar
• 66. Sosa A., Lopez Cadena E., Simon Olive C., Karachaliou N., RosellR.: Clinical assessment of immune-related adverse events. Ther.Adv. Med. Oncol., 2018; 10: 1758835918764628
  Google Scholar
• 67. Tamaskar I., Bukowski R., Elson P., Ioachimescu A.G., WoodL., Dreicer R., Mekhail T., Garcia J., Rini B.I.: Thyroid function testabnormalities in patients with metastatic renal cell carcinomatreated with sorafenib. Ann. Oncol., 2008; 19: 265–268
  Google Scholar
• 68. Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachernM.P., Shen L.Y., Redman B., Gianchandani R.: Spectrum of immunecheckpoint inhibitors-induced endocrinopathies in cancerpatients: A scoping review of case reports. Clin. Diabet. Endocrinol.,2019; 5: 1
  Google Scholar
• 69. Torino F., Barnabei A., Paragliola R.M., Marchetti P., SalvatoriR., Corsello S.M.: Endocrine side-effects of anti-cancer drugs: mAbsand pituitary dysfunction: clinical evidence and pathogenic hypotheses.Eur. J. Endocrinol., 2013; 169: R153–R164
  Google Scholar
• 70. Verloop H., Smit J.W., Dekkers O.M.: Sorafenib therapy decreasesthe clearance of thyrotropin. Eur. J. Endocrinol., 2013; 168:163–167
  Google Scholar
• 71. Veroux M., Tallarita T., Corona D., Sinagra N., Giaquinta A.,Zerbo D., Guerrieri C., D’Assoro A., Cimino S., Veroux P.: Conversionto sirolimus therapy in kidney transplant recipients with newonset diabetes mellitus after transplantation. Clin. Dev. Immunol.,2013; 2013: 496974
  Google Scholar
• 72. Walko C.M., Aubert R.E., La‐Beck N.M., Clore G., Herrera V.,Kourlas H., Epstein R.S., McLeod H.L.: Pharmacoepidemiology ofclinically relevant hypothyroidism and hypertension from sunitiniband sorafenib. Oncologist, 2017; 22: 208–212
  Google Scholar
• 73. Wang D.Y., Salem J.E., Cohen J.V., Chandra S., Menzer C., Ye F.,Zhao S., Das S., Beckermann K.E., Ha L., Rathmell W.K., Ancell K.K.,Balko J.M., Bowman C., Davis E.J. i wsp.: Fatal toxic effects associatedwith immune checkpoint inhibitors: A systematic review andmeta-analysis. JAMA Oncol., 2018; 4: 1721–1728
  Google Scholar
• 74. Wong E., Rosen L.S., Mulay M., Vanvugt A., Dinolfo M., TomodaC., Sugawara M., Hershman J.M.: Sunitinib induces hypothyroidismin advanced cancer patients and may inhibit thyroid peroxidaseactivity. Thyroid, 2007; 17: 351–355
  Google Scholar
• 75. Yajima K., Akise Y.: A case report of Graves’ disease inducedby the anti-human programmed cell death-1 monoclonal antibodypembrolizumab in a bladder cancer patient. Case Rep. Endocrinol.,2019; 2019: 2314032
  Google Scholar
• 76. Yang J.C., Reguart N., Barinoff J., Köhler J., Uttenreuther-FischerM., Stammberger U., O’Brien D., Wolf J., Cohen E.E.: Diarrheaassociated with afatinib: An oral ErbB family blocker. Expert Rev.Anticancer Ther., 2013; 13: 729–736
  Google Scholar
• 77. Zhao C., Tella S.H., Del Rivero J., Kommalapati A., EbenuwaI., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment inducedcentral diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103:365–369
  Google Scholar

Full text